Benefits
Cardiometabolic parameter support
Altilix® at 150 mg/day for 6 months was compared with placebo in one trial of 100 adults with metabolic syndrome, 50 per group. The supplement group lost 2.6 kg and 3.5 cm from the waist while the placebo group moved about half a kilo and half a centimetre, and HbA1c fell 0.77 points against a 0.18 point rise on placebo. Cholesterol and triglycerides also moved further in the supplement group.
Hepatic function support
Cynara cardunculus extract lowered the liver enzymes AST and ALT in the 6 month trial, though both were already inside the normal range at the start, with ALT falling from about 27 to 20 U/L. The fatty liver index also fell, but that index is calculated from body mass index, waist, triglycerides and GGT rather than measured in the liver, so it moves largely because weight, waist and triglycerides moved. No liver scan or biopsy was performed.
Lipid profile support
Altilix® supplementation was followed by lower total cholesterol, triglycerides and LDL cholesterol in the one trial of adults with metabolic syndrome. Over 6 months total cholesterol fell about 26 mg/dL and LDL about 19 mg/dL, while the placebo group drifted upward, so part of the gap between the groups comes from placebo worsening rather than from the supplement. HDL cholesterol did not change.
Endothelial function support
Long-term Altilix® supplementation was linked to a rise in flow mediated dilation, an ultrasound measure of how much the artery in the arm widens. Read this one cautiously. The supplement group went from about 21.5 to 26.3 percent while the placebo group fell from 16.9 to 10.9 percent, and both the unusually high starting values and the steep placebo decline are hard to square with what this test normally returns, so the gap between the groups may reflect the measurement as much as the supplement.
Mechanism of action
Chlorogenic acid metabolic effects
Chlorogenic acid moderates intestinal glucose absorption, reduces hepatic gluconeogenesis, and exhibits AMPK-activating effects, all of them proposed explanations for the glucose and lipid changes seen in the single Altilix® trial. These mechanisms come from laboratory work and none of them were measured in that trial.
Luteolin anti-inflammatory and antioxidant activity
The flavone luteolin scavenges reactive oxygen species, inhibits pro-inflammatory cytokine production, and supports Nrf2 mediated antioxidant defenses in cell and laboratory studies. These are proposed explanations rather than anything the human trial measured.
Endothelial NO support
The polyphenol mix in Cynara cardunculus extract reduces local oxidative stress in vascular tissue and helps preserve nitric oxide bioavailability, a proposed explanation for the flow mediated dilation reading, which is itself an uncertain result. Nitric oxide was not measured in the trial.
Clinical trials
Randomized, double-blind, placebo-controlled study of Altilix® standardized extract (150 mg/day) for 6 months in 100 adults with metabolic syndrome. Endpoints: body weight, waist circumference, HbA1c, lipid profile, hepatic function markers, carotid intima-media thickness, and flow-mediated dilation.
100 adults with metabolic syndrome, mean age 63, 50 per group. Average starting HbA1c was 7.3 percent, which is in the diabetes range. 6 months.
Over 6 months the supplement group lost 2.6 kg and 3.5 cm of waist against about half a kilo and half a centimetre on placebo, and HbA1c fell 0.77 points while placebo rose 0.18. Total cholesterol, triglycerides, LDL, AST and ALT all fell; HDL did not change. GGT was measured but its result was never reported on its own, only fed into the fatty liver index. One result does not stand up. Carotid intima media thickness is reported as dropping from 0.92 to 0.60 mm in six months, when artery walls usually thicken by a few hundredths of a millimetre a year and even high dose statin trials manage only to slow that thickening rather than reverse it. A change that large in half a year is not biologically plausible and should not be taken at face value. Bionap supplied all the study material.
Not a second trial. The 2023 paper is a post-hoc analysis of the 50 people in the 2019 study whose body mass index was 25 to just under 30, taken from the same 100 participants and the same two arms, so roughly 25 people per group. Endpoints: body weight, glycemic markers, lipid profile, hepatic function, carotid intima-media thickness, and flow-mediated dilation.
50 adults with metabolic syndrome and a body mass index of 25 to under 30, a subgroup of the 100 in the single trial, so about 25 per arm. 6 months.
Within this subgroup the supplement arm again showed lower body weight, better glucose and lipid readings and lower liver enzymes than placebo. Because these are the same people measured in the same study, this adds no independent evidence and should not be counted as a second trial. Post-hoc subgroups of about 25 per arm are also easy to overinterpret.